Background-Platelet activating factor (PAF) has been implicated in the pathogenesis of airway hyperresponsiveness in asthma. The purpose of this study was to evaluate the effects of a selective PAF antagonist (WEB 2086), given in doses known to antagonise the effects of inhaled PAF in human subjects, on allergen induced early and late asthmatic responses and on airway hyperresponsiveness.
Methods-Eight atopic, mildly asthmatic subjects were studied during a screening period and two treatment periods. During the screening period subjects inhaled an allergen to which they were known to be sensitised and the response was measured as the fall in the forced expired volume in one second (FEV1) to show the presence of early (0-1 h) and late (3-7 h ) asthmatic responses. On another day the subjects inhaled allergen diluent. During the treatment periods subjects inhaled allergen after one week's pretreatment with WEB 2086 (100 mg three times a day) or placebo administered in a randomised, double blind, crossover fashion. Histamine airway responsiveness was measured 24 hours before and 24 hours after allergen and the results were expressed as the provocative concentration causing a 20% fall in FEV, (PC20 Inhalation of environmental allergens is an important cause of exacerbations of asthma.
In the laboratory allergen inhalation tests are a useful tool for investigating the pathogenesis of allergen induced asthma. Allergen inhalation causes narrowing of the airways, in sensitised subjects, usually within 15 minutes. This early asthmatic response resolves within two to three hours. In half or more adult subjects a late bronchoconstrictor response, which begins three to four hours after allergen inhalation, also occurs.' The late asthmatic response is more prolonged than the early response and is associated with airway hyperresponsiveness to bronchoconstrictor stimuli such as histamine or methacholine,' and this can last for days or weeks after exposure to allergen. 3 The early asthmatic response occurs because of the release of bronchoconstrictor mediators such as histamine,4 the sulphidopeptide leukotrienes,5 6 and thromboxane A2.78 The late response and subsequent airway hyperresponsiveness is associated with an inflammatory response, shown by an influx of inflammatory cells such as eosinophils,9 into the airways. However, the precise role of the inflammatory cells in causing late asthmatic responses is not yet known.
Platelet activating factor (PAF) is a potent proinflammatory mediator derived from the metabolism of phospholipids from cell membranes and released from a variety of cells, including basophils, macrophages, neutrophils, and eosinophils.10 It has various actions, which include the recruitment and activation of inflammatory cells, particularly eosinophils and neutrophils."1 Inhaled PAF also causes bronchoconstriction and airway hyperresponsiveness in normal subjects'2 1' and is released into the plasma after allergen inhalation in mildly asthmatic subjects. ' Ten subjects were originally entered into the study. Eight subjects completed all parts of the study and were included in the statistical analysis. All subjects were studied in the asthma research laboratories of McMaster University Medical Centre. The subjects were chosen because they had a history of mild, stable, asthma and allergy to an environmental allergen (table) . The subjects were taking inhaled P2 agonists only infrequently, and no subject had taken any other asthma drugs for more than one year. Subjects had not been currently exposed to allergens to which they were sensitised (with the exception of the housedust mite) and had had no exacerbations of asthma for at least four weeks. The baseline forced expiratory volume in one second (FEVy) was more than 75% of predicted normal values19 in all subjects on all study days. The study was approved by the hospital ethics committees, and each subject gave written informed consent before beginning the study. Two subjects were entered but did not complete the study. One subject did not have a late asthmatic response during the screening period and was not entered into the randomisation periods. A second subject entered the randomisation periods and received placebo treatment during the first period, but the histamine airway responsiveness did not return to baseline values before starting the second randomisation period and the subject was withdrawn from the study before allergen inhalation, a histamine inhalation test was performed to document the change in airway responsiveness after allergen inhalation.
The two treatment periods consisted of eight study days each. During the treatment periods subjects were randomly allocated to receive either WEB 2086 100 mg or placebo administered orally three times daily for seven days before, on the day of, and on the day after allergen inhalation. The allergen inhalation tests were carried out one hour after a dose of treatment. A histamine inhalation test was performed the day before beginning the treatment, after six days of treatment, one day before the allergen inhalation, and the day after allergen inhalation. A blood sample was obtained just before the ingestion of the treatment on the allergen inhalation day for measurement of plasma WEB 2086 concentrations. The study was double blind, randomised, and with a crossover design.
The screening and the two treatment periods were separated by at least two weeks. The response to inhaled allergen was determined partly by the degree of airway responsiveness. Therefore, each study period was started only when histamine airway responsiveness had returned to within a single doubling concentration of the initial value during the screening period. Inhaled P2 agonists were withheld for at least eight hours before either the histamine or the allergen inhalation tests. Blood samples were collected as described in the section on the study design and the plasma was stored at -70°C until analysis. WEB 2086 was analysed by using a titrated radioimmunoassay with a sensitivity for WEB 2086 in plasma of 0 1 ng/ml and negligible cross reactivity with its known metabolites (<O 1%).
ANALYSIS
The primary end point of the study was evaluation of the ability of pretreatment with WEB 2086 to inhibit allergen induced late asthmatic responses. The effect of WEB 2086 on histamine airway responsiveness, allergen induced early asthmatic responses, and allergen induced increases in histamine airway responsiveness were also compared with the effects of placebo.
All analyses of histamine PC20 were performed on log transformed data, with summary statistics being expressed as geometric means and 95% confidence intervals. All other summary statistics are expressed as arithmetic means with standard errors of the mean. The bronchoconstrictor responses during the early (up to one hour) and late (three to seven hours) asthmatic responses with saline, placebo, and WEB 2086 were compared using two way analysis of variance appropriate for repeated measures data.
Comparison of the log difference (the arithmetic ratio) of histamine PC20 24 hours before and 24 hours after allergen in both study periods is appropriate for assuming the effects of treatment on allergen induced airway hyperresponsiveness, a log difference of 0 signifying no change in airway responsiveness. Log transformed PC20 measurements are normally distributed; therefore, the effect of WEB 2086 and placebo on baseline histamine responsiveness and on the increases in histamine responsiveness after allergen were compared using two tailed Student's t tests for paired observations. Statistical significance was accepted as p < 0-05. The power of the study to detect a 50% inhibition of the late response (the primary end point) by WEB 2086 was evaluated retrospectively. one week does not influence allergen induced asthmatic responses. This study, therefore, does not support a role for PAF as an important mediator in causing the early or late asthmatic responses or the airway hyperresponsiveness after inhaled allergen in asthmatic subjects. However, further studies with an inhaled antagonist to increase availability at the receptor may be warranted. 
